Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with OAG (Open Angle Glaucoma) and using at least 2 topical IOP-lowering medication classes in the study eye
Scheduled to receive surgical treatment with either XEN (Xen gel stent) or trabeculectomy in the study eye
Access to an electronic device with internet capabilities and an email address for completion of PROs (Patient Reported Outcomes)
Be willing and able to complete PROs (Patient Reported Outcomes) at the specified time points
Able to provide voluntary, informed consent to participate in this study
You may not be if
Diagnosed with angle closure glaucoma in the study eye
Presence of a secondary glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma
Presence of neovascular, uveitic, or angle recession glaucoma or any glaucoma associate with vascular disorders
Prior incisional glaucoma surgery, canal-based surgery, suprachoroidal space-based surgery (trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.) or a cilio-ablative procedure
Clinically significant inflammation or infection in the study eye within 30 days prior to the baseline visit (e.g. blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection)
History of corneal surgery, corneal opacities, or corneal disease
Prior intraocular surgery in either eye ≤ 3 months prior to study enrollment with the exception of uncomplicated cataract surgery in either eye ≥ 1 month prior to study enrollment
Anticipated ocular surgery in either eye within 6 months of baseline
Concomitant cataract surgery scheduled at the time of glaucoma procedure
The study eye is defined as the eye receiving surgical intervention with either XEN or trabeculectomy.
